Drug General Information (ID: DDINYBUP5E)
  Drug Name Zidovudine Drug Info Amphotericin B (lipid complex) Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Anti-Hiv Agents Antifungal Agents
  Structure

 Mechanism of Zidovudine-Amphotericin B (lipid complex) Interaction (Severity Level: Moderate)
     Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Zidovudine Amphotericin B (lipid complex)
      Mechanism 1 Myelosuppressive effects Myelosuppressive effects
      Key Mechanism Factor 1
Factor Name Myelosuppressive effects
Factor Description Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
      Mechanism Description
  • Additive myelosuppressive effects by the combination of Zidovudine and Amphotericin B (lipid complex) 
     Increased risk of nephrotoxicity Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Zidovudine Amphotericin B (lipid complex)
      Mechanism 2 Nephrotoxicity Nephrotoxicity
      Key Mechanism Factor 2
Factor Name Nephrotoxicity
Factor Description The combination of drugs that can induce nephrotoxicity may increase the risk of kidney injury. When kidney injury occurs, the inability to remove excess urine and waste from the body can lead to high levels of urea nitrogen, creatinine, and electrolytes (such as potassium and magnesium) in the blood.
      Mechanism Description
  • Increased risk of nephrotoxicity by the combination of Zidovudine and Amphotericin B (lipid complex) 

Recommended Action
      Management If these drugs are used together, the patient's renal and hematologic function should be closely monitored.

References
1 Lotterer E, Ruhnke M, Trautman M, et al "Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal." Eur J Clin Pharmacol 40 (1991): 305-8. [PMID: 2060570]
2 Product Information. Abelcet (amphotericin B). Liposome Company Inc, The, Princeton, NJ.
3 Unadkat JD, Collier AC, Crosby SS, et al "Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal." AIDS 4 (1990): 229-32. [PMID: 2350441]